Navigation Links
Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
Date:2/27/2010

Anson Group, a sponsor for Rare Disease Day, hopes to bring more attention to the need for finding more treatments for diseases which affect a smaller patient population.

Indianapolis, IN (Vocus) February 27, 2010 -- The Anson Group hopes to draw more attention to the urgent need of finding more treatments for rare diseases by partnering with the National Organization for Rare Diseases (NORD) to sponsor Rare Disease Day in the United States, February 28th, 2010.

Anson Group, a regulatory consulting company, has had the privilege of providing regulatory support for multiple products that are indicated for the treatment of a number of rare diseases. Anson has aided clients in obtaining Orphan Drug status (for pharmaceutical entities) and Humanitarian Use Designations (for medical devices) for products intended to treat diseases like gastrointestinal stromal tumor (GIST), mastocytosis and multiple myeloma, as well as multiple sclerosis and amyotrophic lateral sclerosis (ALS). Most recently, Anson Group helped prepare materials for an FDA Advisory Committee meeting regarding a new treatment for Niemann-Pick Type C (NPC) disease.

Anson supports the need for continued research and innovation in rare diseases. As scientists continue to work to evolve treatments to target more specific disease pathways, subpopulations and rare diseases will become increasingly important in the understanding and practice of true personalized medicine. Anson Group will continue to invest in building our expertise in regulatory requirements for these products in order to expand our role in ensuring promising treatments reach the market for those who suffer from rare conditions.

“Anson is proud of our 15 year history of helping all of our clients get their medical technologies to market as quickly as possible and in compliance with the applicable regulations; that said, no project we work on is more gratifying from a personal perspective than working on a product that might only apply to a small percentage of people but enables them to have a better quality of life,” states Gerry Richardson, CEO of Anson Group. “Because Anson is a minority/woman-owned business, we are particularly excited to work with clients who continue to research and develop products that target diseases disproportionately affecting those specific subpopulations.”

About Anson Group
Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting organization with over 15 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly-defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

###

Read the full story at http://www.prweb.com/releases/rare_diseases/regulatory_consulting/prweb3658524.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
2. Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass
3. Novagali Pharma Completes a EUR15 Million Fund Raising
4. Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
5. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
6. Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month
7. Accera, Inc. to Support the Alzheimers Foundation of Americas National Memory Screening Day Through On-line Awareness Effort
8. TSH Testing Raises Awareness of Importance of Thyroid Health
9. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
10. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
11. Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
(Date:3/28/2017)... and WASHINGTON , March 28, ... provider, GENEWIZ, will launch single-cell sequencing during the American Association ... E. Washington Convention Center in Washington, D.C. ... to perform differential gene expression of thousands of cells ... Experts on-hand at AACR ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... international life sciences corporation Anpac Bio-Medical Science ... a new, international record, processing and reporting over ... "Cancer Differentiation Analysis" (CDA) liquid biopsy tests. ... Nobel Prize Laureate Summit publications, Anpac Bio,s CDA ...
(Date:3/28/2017)... , March 28, 2017 ... and unpredictable sector due to the scientifically intensive ... include medical, agricultural, environmental, and industrial. In today,s pre-market ... Portola Pharmaceuticals Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: ... Therapeutix Inc. (NASDAQ: OCUL ). Learn ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Harvill as Chief Executive Officer with Avomeen Analytical Services. Harvill is a distinguished ... and operations. , Avomeen is a leader in a wide range of ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):